Sandoz US launches first generic paclitaxel for metastatic breast cancer treatment, approved by FDA on October 8, 2024.

Sandoz US has launched a generic paclitaxel formulation in the US, following FDA approval on October 8, 2024. This product, the first generic referencing Sandoz's albumin-bound paclitaxel, is intended for treating metastatic breast cancer. Developed with Jiangsu Hengrui Pharmaceuticals, the single-dose vial aims to enhance access to treatment for the 168,000 women in the US affected by this condition and is expected to drive growth in Sandoz's oncology portfolio.

October 11, 2024
6 Articles